Skip to main content
Premium Trial:

Request an Annual Quote

NIH Offers up to $2M for Genotype Data Analysis Methods

NEW YORK (GenomeWeb News) – The National Institutes of Health wants researchers to develop advanced statistical methods that could be used to analyze complex data sets for the influences of genetic variation on tissue-specific gene expression and regulation.

NIH will grant up to $1 million per year over two years to fund two or three research projects that will develop methods that can be used to analyze data sets that are forthcoming from the NIH Roadmap initiative’s Genotype-Tissue Expression (GTEx) Project.
The “Novel statistical methods for human gene expression quantitative trait loci (eQTL) analysis,” program will grant between $200,000 and $300,000 to researchers who will study pre-existing gene expression datasets and, as they become available, data sets from the GTEx program.

All proposed projects must be relevant to eQTL mapping, and those that focus entirely or predominantly on human data, and comparing it to mammalian systems, will have the highest priority, NIH said.

Some examples of the types of studies applicants may seek funds for include those that aim to extend existing methods or develop new methods of integrating and analyzing genotype and gene expression data and regulatory networks; extend or develop new models to make predictions about functional relevance of genetic variants to gene regulation; modifying data reduction tools that can make analysis more efficient; and modeling and exploring the overlap in eQTLs between different tissues.

The funds may also support the development of methods to use multiple datasets or multiple tissue types to reduce the number of false negative results, and the development of creative methods to quantify RNA expression levels from next-generation sequencing data, comparing it to chip-based estimates, and evaluating its impact on the ability to identify eQTLs.

More information on the funding opportunity can be found here.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.